JP2016510998A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510998A5 JP2016510998A5 JP2016501146A JP2016501146A JP2016510998A5 JP 2016510998 A5 JP2016510998 A5 JP 2016510998A5 JP 2016501146 A JP2016501146 A JP 2016501146A JP 2016501146 A JP2016501146 A JP 2016501146A JP 2016510998 A5 JP2016510998 A5 JP 2016510998A5
- Authority
- JP
- Japan
- Prior art keywords
- mouse
- polypeptide
- human
- item
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 description 55
- 108090000765 processed proteins & peptides Proteins 0.000 description 55
- 102000004196 processed proteins & peptides Human genes 0.000 description 55
- 239000002773 nucleotide Substances 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 26
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 15
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 15
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 12
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 101000937526 Mus musculus Beta-2-microglobulin Proteins 0.000 description 5
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108700043516 mouse H-2Kb Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/793,812 US9591835B2 (en) | 2011-10-28 | 2013-03-11 | Genetically modified major histocompatibility complex animals |
| US13/793,812 | 2013-03-11 | ||
| PCT/US2014/023076 WO2014164640A1 (en) | 2013-03-11 | 2014-03-11 | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510998A JP2016510998A (ja) | 2016-04-14 |
| JP2016510998A5 true JP2016510998A5 (cg-RX-API-DMAC7.html) | 2017-04-13 |
| JP6456351B2 JP6456351B2 (ja) | 2019-01-23 |
Family
ID=50513441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501146A Active JP6456351B2 (ja) | 2013-03-11 | 2014-03-11 | キメラ主要組織適合複合体（ｍｈｃ）クラスｉ分子を発現する遺伝子導入マウス |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2967014B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6456351B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102313053B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105188358B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014249150B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2902543A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2764829T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014164640A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| SMT201900429T1 (it) | 2013-02-20 | 2019-09-09 | Regeneron Pharma | Topi esprimenti co-recettori umanizzati linfociti t |
| EP2958937B1 (en) | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| US10316094B2 (en) | 2014-10-24 | 2019-06-11 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance |
| US10550187B2 (en) | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
| DK3280257T3 (da) * | 2015-04-06 | 2023-09-04 | Regeneron Pharma | Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr |
| CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| US20220340926A1 (en) * | 2019-05-27 | 2022-10-27 | Transgenic Inc. | Exon-humanized mouse |
| US10841728B1 (en) | 2019-10-10 | 2020-11-17 | Boomcloud 360, Inc. | Multi-channel crosstalk processing |
| EP4087392A4 (en) * | 2020-01-10 | 2024-02-21 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC MHC PROTEIN COMPLEX |
| AU2022249328A1 (en) | 2021-03-31 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire |
| EP4215042A1 (en) | 2022-01-21 | 2023-07-26 | Max-Delbrück-Centrum für Molekulare Medizin | A non-human mammal comprising in its genome at least two human leukocyte antigen (hla) class i alleles, methods of making such mammal and uses thereof |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489742A (en) * | 1990-10-23 | 1996-02-06 | Board Of Regents, The University Of Texas System | Transgenic rats and animal models of inflammatory disease |
| US20020151690A1 (en) * | 1997-08-12 | 2002-10-17 | Luxemburg Alain T | Purification of antigen-specific t cells |
| SK14832001A3 (sk) * | 1999-04-23 | 2003-02-04 | Pharmexa A/S | Analóg interleukínu 5, fragment nukleovej kyseliny, vektor, bunka, prípravky a použitie |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JPWO2002047474A1 (ja) | 2000-12-13 | 2004-04-15 | 住友製薬株式会社 | Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用 |
| FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| CA2474002A1 (en) * | 2002-01-18 | 2003-07-24 | Bjarne Bogen | Bispecific antibody dna constructs for intramuscular administration |
| SE0301109D0 (sv) * | 2003-04-14 | 2003-04-14 | Mallen Huang | Nucleotide vaccine composition |
| US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| PL1802193T3 (pl) | 2004-10-19 | 2014-09-30 | Regeneron Pharma | Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| LT3262932T (lt) * | 2011-10-28 | 2019-08-26 | Regeneron Pharmaceuticals, Inc. | Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu |
-
2014
- 2014-03-11 WO PCT/US2014/023076 patent/WO2014164640A1/en not_active Ceased
- 2014-03-11 ES ES14718226T patent/ES2764829T3/es active Active
- 2014-03-11 AU AU2014249150A patent/AU2014249150B2/en active Active
- 2014-03-11 CA CA2902543A patent/CA2902543A1/en active Pending
- 2014-03-11 CN CN201480025263.6A patent/CN105188358B/zh active Active
- 2014-03-11 EP EP14718226.5A patent/EP2967014B1/en active Active
- 2014-03-11 KR KR1020157028380A patent/KR102313053B1/ko active Active
- 2014-03-11 JP JP2016501146A patent/JP6456351B2/ja active Active
-
2020
- 2020-07-01 AU AU2020204410A patent/AU2020204410C1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510998A5 (cg-RX-API-DMAC7.html) | ||
| JP2014532412A5 (cg-RX-API-DMAC7.html) | ||
| JP7261772B2 (ja) | ヒト化ｔ細胞補助受容体を発現するマウス | |
| JP2018126170A5 (cg-RX-API-DMAC7.html) | ||
| JP2023174872A (ja) | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 | |
| JP2016506761A5 (cg-RX-API-DMAC7.html) | ||
| JP6574457B2 (ja) | 遺伝子改変された主要組織適合複合体マウス | |
| CN110192541B (zh) | 表达人源化主要组织相容性复合物的小鼠 | |
| AU2020204410C1 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules | |
| AU2012324016B8 (en) | Genetically modified major histocompatibility complex mice | |
| JP2019068857A5 (cg-RX-API-DMAC7.html) | ||
| US20180288986A1 (en) | Genetically modified major histocompatibility complex animals | |
| HK1249712A1 (en) | Genetically modified major histocompatibility complex mice | |
| JP2016523561A5 (cg-RX-API-DMAC7.html) | ||
| CN104131036B (zh) | 条件型伊维菌素受体ivmr转基因小鼠模型的构建方法及应用 | |
| RU2653433C2 (ru) | Генетически модифицированные в отношении главного комплекса гистосовместимости мыши | |
| KR20250077529A (ko) | 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스 | |
| HK40106351A (en) | Genetically modified major histocompatibility complex mice | |
| BR122019026475B1 (pt) | Composição e método para produzir um camundongo geneticamente modificado |